Answers are grounded in this paper and cite their sources.
INTEREST has increased over the past few years in the use of technetium 99m as a radioactive tracer material for organ and tumor localization studies (1). Initially, attention was focused on this nuclide because of its favorable physical properties for biological applications (2). Subsequent chemical and physiological studies have revealed remarkably versatile characteristics which may make Tc99m the radioisotope of choice in a variety of clinical applications (3–13). This report summarizes the progress made in our laboratory during the past four years in investigating this isotope. Chemically technetium belongs in group VII-A along with manganese and rhenium, the resemblance to the latter being particularly close. The physiologic behavior of technetium compounds has not been extensively studied except for the pertechnetate. This rather stable ion resembles iodide very closely in its initial distribution in the body (14). Like iodide it is selectively concentrated in the thyroid, salivary glands, and stomach, and selectively excluded from the cerebrospinal fluid (16). The selective concentration is abolished by perchlorate as in the case of iodide, presumably by competitive inhibition. Pertechnetate is bound to circulating protein more firmly (14, 17) than iodide and apparently is slowly changed in the body to other chemical forms making its secretion slower (14, 15). Studies are continuing on the physiological behavior of pertechnetate as well as other technetium compounds. When reduced to a lower valence (18), technetium appears to combine avidly with a variety of materials to form stable compounds or complexes so that a wide field for such investigation is open. The favorable physical characteristics (Fig. 1) of technetium 99m consist of a short, but not too short, physical half-life of six hours, the emission of a clean 140 kev gamma ray, and the absence of primary particle radiation. The energy deposition in tissue is thus extremely small. The effective Eβ due to conversion electrons (∼8 per cent of the 140 kev γ) and low energy gamma and fluorescent photons is 0.014 Mev, and the Iγ is 0.56 Rzrnc hour at 1 ern (0.70 if K fluorescent radiation is included). Assuming no excretion, dose calculations give 320 mrad/mc to the stomach and 10 mrad total-body irradiation when pertechnetate is injected intravenously (19). The radioactive daughter, Tc99, arising from decay of Tc99m, gives trivial radiation dosage, even if complete retention is assumed, because the amount of radioactivity is reduced so greatly due to the long half-life of Tc99 (2 × 105 γ). One millicurie Tc99m decays to 3.3 × 10-9 mc Tc99. Excretion of Tc99m after administration of pertechnetate is rapid during the first twenty-four hours, mostly in the urine.
No takes yet. Share an insight, caveat, or question.
Harper et al. (1965) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: